CTIS2022-500338-27-00进行中（未招募）1 期
CAT-Trial: CGRP monoclonal Antibody for Treatment of painful diabetic neuropathy: a double-blind, multicenter, placebo-controlled, international phase II clinical trial
Aarhus University Hospital0 个研究点目标入组 100 人开始时间: 2022年11月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age 18 – 75 years, Confirmed diagnosis of probable diabetic polyneuropathy, as defined by the Toronto consensus criteria and a TCNS > 5 or abnormal DPNCheck or abnormal NCS, Probable neuropathic pain as defined by the NeuPSIG guidelines, Symmetric distal pain worse in the distal lower extremities present for >6 months, Average pain score on a NRS of =4 during the baseline week
排除标准
- •Prior or current use of a CGRP mAbs or CGRP antagonists, Planned larger surgery in the treatment period, Chronic wounds, Unable to understand Danish (Danish site only), All female subjects of childbearing potential must have negative result of a serum pregnancy test performed at screening. Subjects of childbearing potential must agree to use a medically approved form of birth control (abstinence, intrauterine device (IUD), oral contraception, barrier and spermicide or hormonal implant) throughout the duration of the study., Pregnant or planning to become pregnant during the duration of the study, Opioid regimen other than stable low dose of Tramadol (maximum 200 mg/day), Lifetime history of psychosis, bipolar mania, or dementia. Patients with other psychiatric conditions whose symptoms are not controlled or who have not been adequately treated for a minimum of 6 months prior to screening are also excluded, Initiation of new neuropathic pain medications such as gabapentinoid medications (gabapentin, pregabalin) and/or capsaicin (Quetenza), botulinum toxin type A, serotonin/norepinephrine reuptake inhibitors (TCA or duloxetine or venlafaxine) 1 month prior to enrollment or for the duration of the randomized placebo-controlled phase of the study. Current and ongoing pain treatment will be allowed in stable dose (anticonvulsants, antidepressants, tramadol, topical treatments (excluding high dose capsaicin patch and botulinum toxin type A) (Paracetamol 1g and over-the-counter NSAIDS as needed up to four times daily are allowed as rescue medicine), Suspected cause of lower extremity pain of other causes than diabetes (e.g. chemotherapy, alcohol or drug misuse, vitamin deficiency, concomitant central nervous system pathology) or patients with pain that cannot be distinguished from their neuropathic pain in the feet due to diabetes, The patient has a history of clinically significant cardiovascular disease, including uncontrolled hypertension, ischaemia or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism), BMI =39 kg/m2 at the screening visit, Peripheral arterial disease (PAD) defined as toe pressure <40mmHg, no palpable foot pulses or clinical claudicatio intermittens
研究者
相似试验
已完成
不适用
The effects of CGRP pathway monoclonal antibody treatment on inner ear function in patients with migraine: a prospective studymigraineJPRN-UMIN000048360Tominaga Hospital25
进行中（未招募）
1 期
Obinutuzumab (GA101) in combination with PixantrOne for the treatment of patients with relapsed Aggressive B-cell LymphomaEUCTR2014-004780-21-DEniversity Medical Center of the Johannes Gutenberg70
撤回
2 期
A Study of CGRP Monoclonal Antibody to Treat Diabetic NeuropathyDiabetic PolyneuropathyNCT05937152Mayo Clinic100
已完成
4 期
Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/FibromyalgiaGlossopharyngeal NeuralgiaTrigeminal NeuralgiaNCT04158752Duke University26
进行中（未招募）
3 期
Resected Stage III Melanoma With Macroscopic InvolvementACTRN12609000099224GlaxoSmithKline Biologicals1,300